Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134910
Abstract: Introduction: Both anti-apoptosis and pro-survival mechanisms promote myeloma cell growth and proliferation, and B-cell lymphoma-2 (BCL-2) is over-expressed in a subset of myeloma patients (pts). Venetoclax (V; orally administered BCL-2 inhibitor) monotherapy has demonstrated efficacy… read more here.
Keywords: kras braf; combination; nras kras; response ... See more keywords